HBIO Stock Overview
Develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Harvard Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.02 |
| 52 Week High | US$5.56 |
| 52 Week Low | US$2.70 |
| Beta | 1.31 |
| 11 Month Change | -8.48% |
| 3 Month Change | -2.58% |
| 1 Year Change | -31.83% |
| 33 Year Change | -63.44% |
| 5 Year Change | 27.97% |
| Change since IPO | -71.24% |
Recent News & Updates
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Aug 07
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
Jul 15Recent updates
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Aug 07Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
Jul 15Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?
Dec 28Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Dec 11Shareholder Returns
| HBIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 6.3% | -0.6% | 0.1% |
| 1Y | -31.8% | 3.8% | 24.9% |
Return vs Industry: HBIO underperformed the US Life Sciences industry which returned 3.8% over the past year.
Return vs Market: HBIO underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| HBIO volatility | |
|---|---|
| HBIO Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: HBIO's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 404 | Jim Green | www.harvardbioscience.com |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.
Harvard Bioscience, Inc. Fundamentals Summary
| HBIO fundamental statistics | |
|---|---|
| Market cap | US$141.74m |
| Earnings (TTM) | -US$10.68m |
| Revenue (TTM) | US$101.13m |
1.3x
P/S Ratio-12.3x
P/E RatioIs HBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBIO income statement (TTM) | |
|---|---|
| Revenue | US$101.13m |
| Cost of Revenue | US$41.76m |
| Gross Profit | US$59.36m |
| Other Expenses | US$70.04m |
| Earnings | -US$10.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 58.70% |
| Net Profit Margin | -10.56% |
| Debt/Equity Ratio | 53.1% |
How did HBIO perform over the long term?
See historical performance and comparison